With a market capitalization (market cap) of $1.01B — a measure of how much the company is worth — Odyssey Therapeutics, Inc. ranks #2,441 among the 2,447 companies tracked, and 358th in Healthcare as of November 11, 2026. Shares trade at $20.99, up 4.95% on the day.
As of November 11, 2026 · Prices may be delayed
of 2,447 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Listed less than one year ago
Listed less than one year ago
Listed this year; no prior year-end value to compare
Listed less than five years ago
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 11, 2026. The headline market cap is from the ranking update on November 11, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 11, 2026 | $1.01B | — | $20.99 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.01B as of November 11, 2026.
Market cap = share price × shares outstanding.
Odyssey Therapeutics, Inc.'s ranking market cap is the reported market cap from the latest ranking update, with a share price of $20.99 as of November 11, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.01B on November 11, 2026. See how the ranking works.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 47,174,156 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $20.99.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.35T | +0.38% |
| #20 | Johnson & Johnson JNJ | $675.03B | -0.13% |
| #23 |
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 11, 2026, Odyssey Therapeutics, Inc. (ODTX) is worth $1.01B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Odyssey Therapeutics, Inc.’s book equity is about −$488.28M. Market cap is the market value of the outstanding shares. As of November 11, 2026, its market cap is $1.01B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Odyssey Therapeutics, Inc. ranks #2,441 among the 2,447 companies tracked on MarketCapLens. In Healthcare it ranks #358 of 359.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
FY 2025
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $521.41B |
| +0.37% |
| #31 | Merck & Co., Inc. MRK | $362.86B | -0.58% |
| #32 | UnitedHealth Group Incorporated UNH | $361.04B | -0.54% |
| #40 | Novartis AG NVS | $302.78B | -1.80% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2438 | TrustCo Bank Corp NY TRST | $1.01B | -0.46% |
| #2439 | Tuya Inc. TUYA | $1.01B | +0.61% |
| #2440 | Arteris, Inc. AIP | $1.01B | +6.44% |
| #2442 | New Pacific Metals Corp. NEWP | $1B | -3.39% |
| #2443 | Tamboran Resources Corp TBN | $1B | +0.53% |
| #2444 | Apogee Enterprises, Inc. APOG | $1B | +0.17% |
Odyssey Therapeutics, Inc.’s ranking market cap of $1.01B comes from the same snapshot as the rest of this site, as of November 11, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 47,174,156. The historical market-cap series last observed $1.01B on November 11, 2026.
Odyssey Therapeutics, Inc. (ODTX) shares trade at $20.99, up 4.95% on the day, as of November 11, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.